Samsung Bioepis and Daewoong Pharmaceuticals have signed an exclusive supply contract for Samsung Bioepis’ Samfenet, a trastuzumab biosimilar (Original: Herceptin), Daewoong said Monday.
Herceptin is one of the most purchased biomedicine with an estimated 7.8 trillion won ($6.9 billion) in sales. It has applications for early and metastatic breast cancer and metastatic gastric cancer. The Ministry of Drug and Food Safety approved the domestic sales of Samfenet on Nov. 8.
With this agreement, Daewoong has secured a line of anticancer drugs, which include Samsung Bioepis’ Samfenet, Ilyang Pharmaceutical’s Supect and Takeda Pharmaceutical’s Instanyl. The company also sells Takada’s matrifen, an anticancer aid patch.
“Samsung Bioepis’ biosimilars are already recognized in the global market with excellent quality and reasonable prices,” said Lee Jong-wook, CEO of Daewoong Pharma. “The company’s biosimilar is treating more than 70,000 patients in Europe.”
Daewoong Pharmaceutical’s sales right of Samfenet does not mean a mere increase in the number of drugs for the company, but a full-fledged pledge to enter into the anticancer drug market, Lee added.
<© Korea Biomedical Review, All rights reserved.>